Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder

ABSTRACT

Background

Opioid use disorder (OUD) is associated with high healthcare resource utilization (HCRU) and costs. reSET-O is an FDA-cleared prescription digital therapeutic that delivers neurobehavioral therapy as an adjunct to treatment-as-usual (TAU; buprenorphine, face-to-face counseling, and contingency management).

Methods

A budget impact model was developed to evaluate reSET-O as an adjunct to TAU in OUD for a 1 million-member US mixed health plan over a 5-year time horizon. Model inputs included treatment costs and medical costs of hospitalizations, partial hospitalizations, intensive care unit stays, and emergency department visits.

Results

The base-case results and the alternative scenario analysis showed the addition of reSET-O was projected to result in consistently lower total yearly costs vs TAU and no treatment. The estimated total and per member per month (PMPM) budget impact over 5 years was -$763,026 and -$0.0116, respectively. When the upper range of cost estimates was used, the total and PMPM budget impacts over 5 years were -$2,481,563 and -$0.0378, respectively. Sensitivity analysis showed results were most sensitive to the proportion of patients untreated.

Conclusion

The introduction of reSET-O in addition to TAU for OUD has the potential to reduce healthcare resource utilization and costs from 12 weeks up to 5 years.

KEYWORDS:

• Opioid use disorder
• OUD
• budget impact
• cost of care
• digital therapeutic
• prescription digital therapeutic
• PDT
• cognitive behavioral therapy
• reSET-O
• buprenorphine

Declaration of Interests

F Velez is an employee of Pear Therapeutics. Pear Therapeutics contracted Xcenda to assist in the research and completion of this study, and D Huang and L Mody are employees of Xcenda. DC Malone is an employee of Strategic Therapeutics and is a consultant for both Pear Therapeutics and Xcenda. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This study was funded by Pear Therapeutics (US), Inc.